In February this year the EU Falsified Medicines Directive (FMD) came into effect. Rich Quelch assesses this latest regulatory attempt to rid the supply chain of dangerous falsified products and reflects on the industry’s need to keep ahead of the game to future-protect itself.
GLOBALISATION is re-shaping the pharmaceutical market, opening new opportunities for growth, innovation and profit. However, a globally‑dispersed supply chain makes it harder to regulate medical products, as well as detect and respond to falsification. At the same time, it is becoming easier for criminal groups to manufacture fake medicines and print packaging in one country, ship components to another for assembly and distribution, and use offshore companies and bank accounts to remain under the radar.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
In February 2019, the final phase of the FMD was enforced. This pan-European safety system aims to remove falsified medicines from circulation and prevent new ones from entering. It has placed a requirement for every pharmaceutical product to carry a unique identifier sequence in the form of a two-dimensional barcode and a device enabling verification that the medicine’s packaging has not been tampered with.
While the rules imposed under the FMD are much needed – and some would argue, long overdue – the benefits afforded by innovative packaging design in helping to combat this form of public health crime can certainly go above and beyond these requirements, to give patients even greater protection from fake medicines.
The true cost of falsified medicine
Falsified medicine is the production of counterfeit pharmaceutical products that do not adhere to the strict regulatory standards imposed by government agencies to ensure the end user’s safety. This can take various forms, with the key factor being low quality, incorrect or a wrong dosage of ingredients. Falsification can also result from information surrounding the product’s provenance trail, such as the manufacturer, country of manufacture and commercialisation owner. Similarly, the distribution channels logged in its records and documents can be falsified to cover up the original source.
It is crucial that consistency, quality control and containment measures are universally applied to protect global health
Any person in any healthcare system in the world can become a victim of fake medicine. Proportionately, patients in poorer countries are most at risk and if this rising trend continues, it serves to widen existing health inequalities. For example, the total number of substandard and falsified medicines circulating in low- and middle-income countries is estimated to be 13.6 percent overall1 and as high as 19.1 percent for antimalarials. This is shocking considering nearly half of the world’s population is at risk of contracting malaria.2 In comparison, in wealthy countries the threat level remains low through legitimate channels, but falsified medicines continue to be sold, particularly online. Prime examples are lifestyle medicines, such as products that allegedly promote weight loss, increase levels of energy and concentration and alleviate sexual dysfunction. The combined effect is the spreading of falsified medicines in countries that are poor, war-torn and in need of aid due to necessity, and households across the world due to desire, curiosity and availability.
With the risks ranging from low quality replicas to entirely unsafe ingredients, it is crucial that consistency, quality control and containment measures are universally applied to protect global health.
The challenges ahead
The FMD should be credited with attempting to unify a European response to the issue of falsified medicines. The pharmaceutical industry, by its very nature, is complex in much the same way as cross‑border political collaboration. Put the two together and it is certainly not an easy task. Looking at the short-term challenges, one that stands out is the interpretation of the directive by member states; because directives merely set out a goal that all EU countries must work towards, leaving the manner of implementation at the discretion of the member states. While the rules on serialisation are clear, the FMD provides far less detail regarding tamper-evidence, other than making its use mandatory. It is up to individual governments to encourage pharmaceutical manufacturers to adopt innovative tamper-proof devices or to achieve a minimum level of security. Some will go further than others.
If anything, leaving the EU could mean the UK Government places even greater responsibility on the pharmaceutical industry to protect patients from falsified medicine
A longer-term hurdle to overcome in the fight against fake medicines is extending this unified approach beyond the EU collective. Politically, the EU Parliament cannot dictate the strategies of non-member states, which means the FMD loses its effect at a global level.
Switzerland is the world’s second largest exporter of medication ($41.3 billion in 2017), the US is the fifth ($21.1 billion) and India is the 10th ($11.9 billion).3 Each of these large global players in the pharmaceutical market has their own national strategies in place, which legally do not have to align with the EU’s directive.
The rise of internet pharmacies (or so-called e-pharmacies) also makes it difficult to eliminate falsified medicines. All authorised e-pharmacies must now display a distinctive logo to demonstrate that they abide by new EU rules; but unsurprisingly non-authorised sellers will continue business as normal. It is therefore ultimately up to consumers to make educated decisions when buying medicine online.
Brexit also further complicates the UK’s position when it comes to adhering to the FMD. While the UK’s relationship with the EU is still unclear at the time of writing, the signals so far have been positive from the UK pharma industry and National Health Service (NHS) leaders who have publicly praised the directive as a world-class system. Along with growing pressure on the UK Government – from bodies like the British Medical Association (BMA) – to fund the equipment necessary to adhere to new serialisation rules under the FMD, it is likely that the UK will see similar product regulation in some capacity, whether through the EU directive or some other channel.
If anything, leaving the EU could mean the UK Government places even greater responsibility on the pharmaceutical industry to protect patients from falsified medicine and become a world leader in tamper-proof design.
Going above and beyond FMD compliance
The comprehensive and fast-evolving nature of endto- end drug traceability means FMD compliance should not be considered end of the road. Investing in the development of the next generation of tamper-proof technology is a worthwhile activity for any pharmaceutical manufacturer, no matter how big or small.
For example, the limitations of printed code have long been exploited by counterfeiters around the world and companies are developing or purchasing technologies to help render cloning or tampering attempts unsuccessful.
Smart tracking systems, which are built into primary and secondary packaging, is another exciting area of innovation within the pharmaceutical industry. By managing and recording all the typical activities that take place in the supply chain or a range of special requirements, tracking chips can log events or raise queries that occur across a product’s lifespan remotely and in real time. This is invaluable information for anti‑tampering strategies, allowing companies to locate and interrogate a product anywhere in the supply chain. For example, the geographical location of a product and the route it took to arrive there can all be captured and stored, thus revealing any unauthorised journey routes or interventions.
Developments in end-to-end traceability strategies are also producing vast amounts of data, which can be analysed and leveraged by pharma companies to increase efficiencies and streamline the supply chain network. Despite extensive scientific innovations to discover, develop and market new medicines more efficiently, many companies have failed to give the same attention to their legacy supply chains. Even those with annual revenues in the billions do not currently have full insight into their supply chain from beginning to end.
With biologic and personalised medicine already re-shaping the industry, there needs to be a two-way street where information can be used to inform the downstream flow of products. Artificial intelligence (AI) is already transforming pharmaceutical supply chains, making intelligent decisions and recommendations for optimal actions. It is data that holds the key to creating efficient, safe and demand-driven supply chains, which benefit manufacturers, health systems and above all, patients.
About the author
Rich Quelch has worked with experts in the healthcare and pharmaceutical sector for almost 10 years. As part of his current role with Origin, Rich aims to raise awareness amongst the pharma community about key issues facing the sector, including increasing sustainability across the supply chain, the latest tamperproof technologies and innovations in child-resistant primary packaging.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.